Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
Status:
Completed
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well selumetinib sulfate works in treating patients with
pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where
it started to nearby tissue or lymph nodes or other places in the body. Selumetinib sulfate
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.